IPIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IPIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Innovation Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means Innovation Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2023 to Sep. 2023 .
Innovation Pharmaceuticals's change in receivables for the fiscal year that ended in Jun. 2023 was $0.00 Mil. It means Innovation Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .
Innovation Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Innovation Pharmaceuticals's liquidation value for the three months ended in Sep. 2023 was $-4.64 Mil.
The historical data trend for Innovation Pharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovation Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Innovation Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovation Pharmaceuticals (OTCPK:IPIX) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Innovation Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Innovation Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Innovation Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 0.864 | - | 5.505 | + | 0.75 * 0 | + | 0.5 * 0 |
= | -4.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Arthur Peter Bertolino | officer: Pres. & Chief Medical Officer | C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915 |
Jane A. Harness | officer: Vice President | 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915 |
Mark Robert Tobin | director | C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190 |
Zorik Spektor | director | 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496 |
Barry A Schechter | director | 7814 TENNYSON CT., BOCA RATON FL 33433 |
Leo Ehrlich | director, 10 percent owner, officer: Chief Financial Officer | C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880 |
Krishna Menon | director, 10 percent owner, officer: President-Chief Scient.Officer | 10 BRIDLE WAY, NORTH READING MA 01864 |
George W. Evans | director, officer: Chief Executive Officer | 17 IRVING PLACE, PELHAM NY 10803 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 10-25-2021
By Marketwired • 08-28-2023
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 06-21-2023
By ACCESSWIRE ACCESSWIRE • 11-12-2021
By sperokesalga sperokesalga • 02-23-2023
By ACCESSWIRE ACCESSWIRE • 07-22-2022
By Value_Insider Value_Insider • 12-13-2022
By ACCESSWIRE ACCESSWIRE • 06-15-2022
By Marketwired Marketwired • 06-03-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.